AAV manufacturing remains a major bottleneck in gene therapy, limiting scalability, increasing production challenges, and slowing the path to broader patient access.
Virica is pleased to announce its selection under the NRC IRAP Canada–Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences. The project will focus on developing an off-the-shelf enhancer–media solution to improve AAV yield and process robustness in the FUJIFILM Biosciences BalanCD® HEK293 system.
The collaboration combines:
- Virica’s Viral Sensitizers (VSE™), HTV™ platform, DoE frameworks, and analytical capabilities
- FUJIFILM Biosciences’ expertise in media, feed supplements, and scale-up
Together, the teams aim to develop an easy-to-adopt solution for more efficient, scalable AAV production with minimal process change.
Better AAV manufacturing helps bring more gene therapies within reach for more patients.
Read the Full Press Release: HERE